Ms. Jones brings more than 25 years of business leadership experience in the biotechnology and pharmaceutical industries across strategic and operational roles. Prior to transitioning to Chief Executive Officer of Neximmune, she held various positions on the executive team, serving as both Chief Operating Officer and Chief Business Officer. For five years prior to joining NexImmune, Ms. Jones was with Astra Zeneca and its subsidiary MedImmune. From 2013-2015, Ms. Jones was Vice President of Portfolio Strategy and Management at AstraZeneca, where she played an instrumental role in building a scientifically innovative, diverse portfolio creating new value for the company. Prior to that she served as Vice President of Global Strategic Marketing to shape product plans and prepare MedImmune for multiple launches. Previously, Ms. Jones held multiple leadership roles with increasing responsibility at Genentech, where she worked for 16 years, including Head of Immunology and Ophthalmology in Global Portfolio and Product Strategy, Endocrine and Pulmonary Franchise, and Immunology Business Unit Operations and Pipeline Planning. Ms. Jones also serves in a consulting role for various companies and organizations and serves on the Life Science Panel for Springboard Enterprises focused on start-up companies led by women.
Dr. Knight is a seasoned executive with extensive experience leading early- and late-stage immunotherapy product development teams. Prior to joining NexImmune, Dr. Knight led the Yescarta® clinical program at Kite Pharmaceuticals (a Gilead Company) and, prior to that, spent 16 years at Celgene Corporation as a Vice President in Clinical Research. During his tenure at Celgene, he helped lead the development of the company’s IMiD and targeted therapy programs, including thalidomide, lenalidomide, and enasidenib. In addition to his roles at Kite and Celgene, Dr. Knight also led the cancer immunotherapy development program at Sorrento Therapeutics as the company’s Senior Vice President and Head of Clinical Research.
Mr. Trainer has over 20 years of experience in various financial, transactional, strategic and commercial roles in the biopharma industry. Before joining NexImmune, he was Vice President and Head of Partnering and Strategy for MedImmune, the biologics R&D unit of the global pharmaceutical company AstraZeneca. Previous to that role, Mr. Trainer was Vice President, Corporate Development for AstraZeneca as well as the global commercial leader for AstraZeneca’s infection, neuroscience and gastrointestinal therapeutic areas. In these roles he has led multiple significant transactions, including spinouts and financings, divestments, collaborations and in-licenses as well as managing P&L performance. Mr. Trainer also served in Board roles on AstraZeneca investments and continues to work as an advisor to life science companies. Before joining MedImmune / AstraZeneca, Mr. Trainer was as a strategy consultant at Monitor Group, where he worked in healthcare and other industries on various strategic questions including M&A strategy. Mr. Trainer received his MBA from Harvard Business School and his AB from Harvard College.
Dr. Oelke is a scientific co-founder of NexImmune and a pioneer of the artificial Antigen Presenting Cell (aAPC) technology. He is also an expert in cellular immunology and T cell research. Dr. Oelke has more than 20 years of research experience in cancer immunotherapy and has a long-standing interest developing methods for antigen-specific stimulation of T cells for therapeutic use. He has numerous peer-reviewed publications and is a co-inventor on more than 20 patents and patent applications describing NexImmune’s proprietary aAPC technology, with additional pending patent applications in related fields of cancer immunotherapy. Prior to joining NexImmune in 2014, Dr. Oelke was, from 2003-2014, on the faculty at the Johns Hopkins University. Earlier in his career Dr. Oelke, who is a chemist by training, received his Ph.D. in Biology from University of Freiburg, where he first became interested in the critical role of antigen presenting cells and their use in immunotherapy.
Before joining NexImmune, Dr. Zeldis was the Chief Medical Officer and President of Clinical Research, Regulatory, and Safety at Sorrento Therapeutics, as well as the CEO of Celgene Global Health, and Chief Medical Officer of Celgene Corporation. Prior to that he was Celgene’s Senior Vice President of Clinical Research and Medical Affairs and was at Celgene since February 1997. He attended Brown University for an A.B., M.S., followed by Yale University for an M.Phil., M.D., Ph.D. in Molecular Biophysics and Biochemistry (Immunochemistry). Dr. Zeldis trained in Internal Medicine at the UCLA Center for the Health Sciences and Gastroenterology at the Massachusetts General Hospital and Harvard Medical School. He was Assistant Professor of Medicine at the Harvard Medical School, Associate Professor of Medicine at University of California, Davis, Clinical Associate Professor of Medicine at Cornell Medical School, and Professor of Clinical Medicine at the Robert Wood Johnson Medical School in New Brunswick, New Jersey. Prior to working at Celgene, Dr. Zeldis worked at Sandoz Research Institute and Janssen Research Institute in both clinical research and medical development. He has served as a Board member for multiple start-up biotechnology companies and currently serves on the Board for PTC Therapeutics, Soligenix, Immodulon, and NexGel. He has published 122 peer-reviewed articles and 43 US patents.
Dr. Bednarik has over 30 years of experience as a translational scientist and executive specializing in moving promising technologies into product development. He was previously Vice President, Molecular Engineering Unit at Intrexon Corp. where he led a team of scientists developing innovative methods for cellular therapies for cancer. Prior to that, Dr. Bednarik held senior positions at Cardiome Pharma Corporation, Artesian Therapeutics, Inc., and Gene Logic, Inc. and led various projects focused on translational medicine spanning several therapeutic areas including cancer and cardiovascular diseases. Among other accomplishments he created the largest known cardiovascular transcriptomic gene expression database for Gene Logic, Inc. He was also the recipient of a $1.7M DARPA contract in 2006 for the development of a novel non-host method for rapid vaccine manufacture. Earlier in his career, Dr. Bednarik served as a Senior Scientist for Human Genome Sciences (HGS) and completed a post-doctoral fellowship at the Johns Hopkins University Oncology Center.
Mr. Rubin joins NexImmune with over 20 years of experience advising life science companies on investor relations strategies, messaging/communications, capital formation, and capital markets advisory. He has advised and raised capital for biotechnology companies from seed to IPO and beyond. He most recently served as Co-head, Managing Director for Solebury Trout Group and Solebury Capital, the leading life sciences investor relations and capital markets advisory firm. Mr. Rubin previously served as the head of the Biotechnology Capital Markets Intelligence Group at Carson Group/Thomson Financial. He is also on the Board of Trustees for the Histiocytosis Association. Mr. Rubin holds a Bachelor of Arts degree in business administration with a concentration in finance from Franklin & Marshall College.
Dr. Ragheb is the Senior Vice President for Translational Sciences and Medicine at NexImmune and the Scientific Founder of JoMoCo Inc. He previously held the role of Senior Medical Fellow for Immunology at Eli Lilly & Co. Before being recruited to Eli Lilly, he was most recently a Chief Medical Research Officer in the Laboratory of Immunology of the Office of Biotechnology Products, CDER, at the U.S. Food Drug Administration and an Attending Physician on the Allergy-Immunology Service, NIAID. A Senior Clinical Investigator in the Laboratory of Immunology, NEI, at the National Institutes of Health, he is a graduate of the Johns Hopkins University and School of Medicine, and is a diplomate of the American Board of Allergy and Immunology. His work and publications have spanned the fields of retrovirology, gene therapy, immune activation, therapeutic protein immunogenicity and clinical trials in immune tolerance.
Ms. Catterton joins NexImmune with over 20 years of experience in the biotechnology and pharmaceutical industry. During her career, she held positions in executive leadership, risk management, quality management systems, global compliance, design controls and regulatory affairs. Ms. Catterton has worked as an independent consultant for over 15 years to Fortune 500 companies, developing and implementing compliant solutions, dealing with FDA & third-party inspections, Consent Decree and Warning Letter responses and implementation.
Mr. Stover brings over 15 years of accounting, finance, and audit experience serving various life science companies in the U.S. and internationally. Before joining NexImmune, he served as Executive Director, Corporate Controller at Autolus Therapeutics Plc. in London. Mr. Stover served as Director, Financial Reporting for Sucampo Pharmaceuticals, Inc and as Associate Director of External Reporting & Technical Accounting at Iridium Communications Inc. He honed his accounting experience serving as a Senior Manager of Ernst & Young LLP advising U.S. and international companies. Mr. Stover earned a B.A. in Economics from Wittenberg University, a MPA from American University, and is a licensed CPA.
In vitae posuere sapien. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Morbi consectetur lectus at lacus pretium ultrices. Nam ac sem in sapien tempor eleifend. Pellentesque imperdiet felis at cursus fermentum. Vivamus congue, nibh hendrerit efficitur laoreet, libero mauris cursus est, porta blandit urna lectus eget arcu. Nunc non est tortor. Nunc non imperdiet diam. Suspendisse vitae est quis mauris condimentum vulputate et lacinia ex. Sed ullamcorper nisl sed diam rutrum, vel ullamcorper orci imperdiet. Mauris dapibus mi a hendrerit rhoncus. Integer pulvinar massa sit amet eros maximus, id faucibus augue ultricies. Proin vehicula ac nisi non tristique. Cras egestas a odio vitae convallis. Nam commodo justo placerat sapien iaculis, ut blandit metus gravida. Mauris dictum vitae ex quis vehicula.
Ms. Haslbeck brings over 20 years of Human Resource experience and leadership, with over 15 years in the biotechnology and pharmaceutical industries.
Her experience spans startup organizations, pre & post IPO, mergers & acquisitions, as well as established organizations with global presence.
Her expertise has spanned all functions of HR, but she has been instrumental in building commercial, corporate and scientific teams at all levels, as well as Organizational Development initiatives to build and retain both culture and people.
Karen is a Senior Certified Professional in Human Resources (SPHR), is a member of the Society for Human Resource Management (SHRM) and Chesapeake Human Resources Association (CHRA). She also earned a certificate in Employee Relations from Cornell University. Ms. Haslbeck has a Degree in Business Administration from UMBC.
Mr. Schiller has over 20 years of experience in business development, global licensing and commercial development. Most recently, Mr. Schiller served as Director, Global Licensing & Business Development, Immunology at EMD Serono, a business of Merck KGaA. Prior to his time at EMD Serono, Mr. Schiller served as Head of Licensing at Cell Signaling Technology, VP of Business Development at Ensemble Discovery and Senior Director of Business Development at Critical Therapeutics. Mr. Schiller holds a BS in Chemistry from the University of South Florida.
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to NexImmune, its subsidiaries or affiliates. No use of any NexImmune trademark, trade name, or trade dress in this site may be made without the prior written authorization of NexImmune, except to identify the product or services of the company.
© NexImmune. All Rights Reserved. 2021
|cookielawinfo-checbox-analytics||11 months||This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".|
|cookielawinfo-checbox-functional||11 months||The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".|
|cookielawinfo-checbox-others||11 months||This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.|
|cookielawinfo-checkbox-necessary||11 months||This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".|
|cookielawinfo-checkbox-performance||11 months||This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".|